Nov 03, 2022 / 01:15PM GMT
Keyur Parekh - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Good afternoon all, and thank you for joining us. My name is Keyur Parekh, and I cover Novo for Goldman Sachs. It's a pleasure to have the team in London. It's even a better pleasure to have them the day after they made a new lifetime high from a stock price perspective. Congratulations. With that, I'm going to pass it to you, Karsten, to make some opening comments, and then we'll go to Q&A from there.
Karsten Munk Knudsen - Novo Nordisk A/S-Executive VP - CFO & Member of the Management Board
Great. Thank you, Keyur, and thank you to Goldman Sachs for hosting our quarterly London lunch meeting. And what an opening, right? So it's a tough act to follow. But clearly, with the dream team like this with my good colleagues, Ludovic Helfgott from Rare Disease, Martin Lange from Development and Camilla Sylvest from our Commercial Strategy area. Then I think we're set up for a great session today.
We had kind of an unfortunate
Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot